Online inquiry

IVTScrip™ mRNA-Anti-CSF2RA, CAM-3001(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5087MR)

This product GTTS-WQ5087MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CSF2RA gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001161529.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1438
UniProt ID P15509
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CSF2RA, CAM-3001(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ5087MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ14256MR IVTScrip™ mRNA-Anti-ERBB3, RG-7116(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA RG-7116
GTTS-WQ12592MR IVTScrip™ mRNA-Anti-F11, NVS250519(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA NVS250519
GTTS-WQ14454MR IVTScrip™ mRNA-Anti-IGF1R, RO4858696-000(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA RO4858696-000
GTTS-WQ5478MR IVTScrip™ mRNA-Anti-tcdB, CDB-1(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA CDB-1
GTTS-WQ9708MR IVTScrip™ mRNA-Anti-CD3E&GPRC5D, JNJ-64407564(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA JNJ-64407564
GTTS-WQ13333MR IVTScrip™ mRNA-Anti-PDCD1, PF-06801591(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA PF-06801591
GTTS-WQ3794MR IVTScrip™ mRNA-Anti-Factor VIIa substitute, BAY-86-6150(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA BAY-86-6150
GTTS-WQ8282MR IVTScrip™ mRNA-Anti-GHR, HM10560A(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA HM10560A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW